血栓炎症与新诊断骨髓增殖性肿瘤患者高血栓风险相关
该前瞻性研究纳入394例新诊断、未接受降细胞治疗的ET和PV患者,检测7种血浆血栓炎症生物标志物,评估其与血栓风险评分的关联。多变量分析显示高风险患者钙卫蛋白和组织因子水平升高,JAK2V617F等位基因负荷>20%者三种标志物升高,PV患者钙卫蛋白与VETS相关,阿司匹林与正常血小板计数患者较低H3Cit水平相关。
要点
- 高风险ET/PV患者钙卫蛋白和组织因子水平升高
- JAK2V617F负荷>20%者钙卫蛋白等三种标志物升高
- PV患者钙卫蛋白与VETS相关,五种标志物在既往静脉血栓者中升高
核心结论
- 血栓炎症标志物与MPN患者血栓风险评分相关,可能改善风险分层。
研究设计与样本
- 前瞻性纳入394例新诊断、未接受降细胞治疗的ET和PV患者,检测7种血浆血栓炎症标志物。
主要发现
- 全MPN队列多变量分析显示高风险患者钙卫蛋白和组织因子水平高于低风险患者。
- ET患者中同样观察到钙卫蛋白和组织因子升高,PV患者中未观察到。
- JAK2V617F等位基因负荷>20%患者钙卫蛋白等三种标志物水平更高。
- PV患者钙卫蛋白与VETS相关,既往静脉血栓者五种标志物升高。
- 正常血小板计数患者中阿司匹林使用与较低H3Cit水平相关。
临床怎么用
- 钙卫蛋白和组织因子等血栓炎症标志物可能辅助MPN血栓风险分层。
- JAK2V617F负荷>20%提示免疫血栓形成风险,需关注。
- PV患者可结合钙卫蛋白和VETS评估静脉血栓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombotic risk assessment is crucial in newly diagnosed essential thrombocythemia (ET) and polycythemia vera (PV) patients to guide cytoreductive therapy. We assessed whether thromboinflammation biomarkers would be good candidates to improve thrombosis risk stratification. We prospectively enrolled 394 newly diagnosed, cytoreductive therapy-naïve, ET and PV patients. We measured seven plasma biomarkers of neutrophil, monocyte, platelet, and endothelial activation, including NET markers, and evaluated their association with thrombosis risk scores at diagnosis. Multivariable analysis in the whole MPN cohort showed elevated calprotectin and tissue factor levels in high-risk versus low-risk patients using the conventional two-tiered score. This was also observed in ET patients only, but not in PV patients. Patients with a JAK2V617F allele burden >20% showed higher levels of three markers, including calprotectin, supporting its role in immunothrombosis. In PV patients, calprotectin correlated with the Venous Thrombosis Score (VETS), and five markers were elevated in those with prior venous thrombosis. Lastly, aspirin use was associated with lower H3Cit levels in patients with normal platelet counts, confirming its beneficial effect on NET formation. This is the largest study to date linking thromboinflammation markers to thrombotic risk in MPN patients and identifying potential biomarkers for future thrombosis risk scores.
引用
- Guy A, Mansier O, Decilap M, et al. Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms. Leukemia. 2025. PMID: 41436639. doi:10.1038/s41375-025-02836-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。